2023

1. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

   Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study

   Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 10, pp. e341-e347